Analyst Reco. Alkermes plc

Equities

ALKS

IE00B56GVS15

Real-time Estimate Cboe BZX Other stock markets 02:22:12 2024-04-29 pm EDT			5-day change	1st Jan Change
25.07 ^USD	+1.58%		+4.09%	-9.68%

Apr. 09	Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	MT
Apr. 09	Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alkermes Insider Sold Shares Worth $292,740, According to a Recent SEC Filing	Mar. 19	MT
Baird Initiates Alkermes With Outperform Rating, Price Target is $37	Mar. 19	MT
UBS Downgrades Alkermes to Sell From Neutral, Price Target is $25	Feb. 20	MT
Piper Sandler Raises Price Target on Alkermes to $39 From $32.54, Maintains Overweight Rating	Feb. 16	MT
Piper Sandler Adjusts Price Target on Alkermes to $35 From $37, Maintains Overweight Rating	23-10-27	MT
Evercore ISI Upgrades Alkermes to Outperform From In-Line	23-10-24	MT
UBS Initiates Coverage on Alkermes With Neutral Rating, $31 Price Target	23-10-17	MT
Piper Sandler Adjusts Price Target on Alkermes to $37 From $35, Maintains Overweight Rating	23-06-07	MT
Mizuho Adjusts Alkermes Price Target to $40 From $36, Maintains Buy Rating	23-06-07	MT
Stifel Nicolaus Adjusts Alkermes Price Target to $33 From $31, Maintains Hold Rating	23-06-06	MT
HC Wainwright Adjusts Alkermes' Price Target to $34 From $32, Keeps Neutral Rating	23-04-27	MT
Mizuho Securities Adjusts Alkermes Price Target to $36 From $37, Maintains Buy Rating	23-04-27	MT
JPMorgan Adjusts Price Target on Alkermes to $31 From $29, Maintains Neutral Rating	23-04-25	MT
Mizuho Adjusts Alkermes' Price Target to $37 From $36, Keeps Buy Rating	23-04-11	MT
JPMorgan Adjusts Alkermes Price Target to $29 From $33, Maintains Neutral Rating	22-12-06	MT
Mizuho Adjusts Price Target on Alkermes to $36 From $34, Maintains Buy Rating	22-11-22	MT
Piper Sandler Upgrades Alkermes to Overweight From Neutral, Adjusts Price Target to $30 From $26	22-11-03	MT
BofA Securities Upgrades Alkermes to Neutral From Underperform, Adjusts Price Target to $25 From $27	22-10-14	MT
Piper Sandler Starts Alkermes at Neutral With $26 Price Target	22-08-16	MT
Mizuho Securities Adjusts Price Target on Alkermes to $34 From $36, Maintains Buy Rating	22-07-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Alkermes plc

Equities

ALKS

IE00B56GVS15

Analyst Reco.

Filters